Press Releases

Arch Biopartners Announces Completion of GMP Manufacturing of Metablok Vials

TORONTO, Sept. 26, 2018 /CNW/ – Arch Biopartners Inc., (Arch or the Company) (TSX Venture: ARCH) (OTCQB: ACHFF) today announced that Dalton Pharma Services (Dalton) has completed the good manufacturing practice (GMP) glass vial filling stage for Metablok, the Company’s lead drug candidate for preventing acute kidney injury. Over the next six to eight weeks … Read more

Arch Biopartners Engages Dalton Pharma Services for GMP Manufacturing of Metablok

TORONTO, Aug. 14, 2018 /CNW/ – Arch Biopartners, Inc., (Arch or the Company) (TSXV: ARCH) (OTCQB: ACHFF) a portfolio-based biotechnology company, today announced it has engaged Dalton Pharma Services (Dalton) to perform the good manufacturing practice (GMP) campaign for Metablok, (LSALT peptide), the Company’s drug candidate for preventing acute kidney injury. Dalton will be responsible … Read more

Arch Biopartners Receives $332,750 From the Exercise of Warrants

TORONTO, June 26, 2018 (GLOBE NEWSWIRE) — Arch Biopartners, Inc., (Arch or the Company) (TSX-V:ARCH) (OTCQB:ACHFF) a portfolio-based biotechnology company, today announced that it received net proceeds of $332,750 during the current quarter from the exercise of 665,500 warrants with an exercise price of $0.50 per common share.

Arch Biopartners to Seek Regulatory Guidance From the U.S FDA for AB569

TORONTO, June 19, 2018 (GLOBE NEWSWIRE) — Arch Biopartners, Inc., (Arch or the Company) (TSX-V:ARCH) (OTCBB:ACHFF) a portfolio-based biotechnology company, today announced that it will seek regulatory guidance from the U.S.

Arch Biopartners Engages Nucro-Technics To Complete Toxicology Studies To Support Investigational New Drug Application For Metablok

TORONTO, May 22, 2018 (GLOBE NEWSWIRE) — Arch Biopartners, Inc., (Arch or the Company) (TSX Venture:ARCH) (OTCQB:ACHFF) a portfolio-based biotechnology company, today announced it has engaged Nucro-Technics in Scarborough, Ontario to complete the preclinical toxicology and pharmacology studies to support an Investigational New Drug (IND) application for Metablok, the Company’s drug candidate for preventing acute kidney injury.

Arch Biopartners Announces Listing on OTCQB Exchange

TORONTO, May 16, 2018 (GLOBE NEWSWIRE) — Arch Biopartners, Inc., (Arch or the Company) (TSX Venture:ARCH) (OTCQB:ACHFF) a portfolio-based biotechnology company, announced that the Company’s common shares have been approved to begin trading today on the OTCQB Venture Market (OTCQB) under the ticker ACHFF.

Arch Biopartners Completes Pre-IND Meeting with U.S. FDA on LSALT Peptide for Preventing Acute Kidney Injury in Cardiac Surgery Patients

TORONTO, May 08, 2018 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (Arch or the Company) (TSX Venture:ARCH) (OTCBB:ACHFF), announced today it completed a successful pre-IND (Investigational New Drug) meeting via teleconference on April 18 with members of U.S.

Arch Biopartners Announces Issuance of U.S. Patent for Its Novel Antibacterial Drug AB569, Designed to Target Chronic Infection and Antibiotic Resistance

TORONTO, March 27, 2018 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (Arch or the Company) (TSX Venture:ARCH) (OTCBB:ACHFF), announced today that the U.S. Patent and Trademark Office has issued U.S. Patent 9,925,206 protecting the composition and methods of use of its lead anti-bacterial drug candidate, AB569.

Arch Biopartners Granted Pre-Ind Meeting With FDA for Candidate Drug to Prevent Acute Kidney Injury

TORONTO, March 21, 2018 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (Arch or the Company) (TSX Venture:ARCH) (OTCBB:ACHFF), announced today that a Pre-Investigational New Drug (Pre-IND) meeting with the U.S. Food and Drug Administration (FDA) Division of Cardiovascular and Renal Products (DCRP) will take place on April 18, 2018 to review and confirm the key components of a planned IND application for Metablok (LSALT peptide) as a treatment to prevent acute kidney injury.

Arch Biopartners Closes $1.25M Non-Brokered Private Placement Financing

TORONTO, March 09, 2018 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (Arch or the Company) (TSX Venture:ARCH) and (OTCBB:ACHFF), announced today it has closed the non-brokered private placement the Company disclosed in a press release January 26, 2018 (The “Offering”).

Arch Biopartners Announces Completion of GMP Manufacturing of Metablok Vials

Arch Biopartners Engages Dalton Pharma Services for GMP Manufacturing of Metablok

Arch Biopartners Receives $332,750 From the Exercise of Warrants

Arch Biopartners to Seek Regulatory Guidance From the U.S FDA for AB569

Arch Biopartners Engages Nucro-Technics To Complete Toxicology Studies To Support Investigational New Drug Application For Metablok

Arch Biopartners Announces Listing on OTCQB Exchange

Arch Biopartners Completes Pre-IND Meeting with U.S. FDA on LSALT Peptide for Preventing Acute Kidney Injury in Cardiac Surgery Patients

Arch Biopartners Announces Issuance of U.S. Patent for Its Novel Antibacterial Drug AB569, Designed to Target Chronic Infection and Antibiotic Resistance

Arch Biopartners Granted Pre-Ind Meeting With FDA for Candidate Drug to Prevent Acute Kidney Injury

Arch Biopartners Closes $1.25M Non-Brokered Private Placement Financing

Contact Arch Biopartners

Stay connected!

Contact Arch Biopartners

Quick Links

Legal

Connect

Mailing Address